To gain insight into possible mechanisms by which pMSCs could be modifying the expression of MCL-1 and BCL-2 proteins in MM cells and eventually affecting the efficacy of S63845 and venetoclax, we focused on post-transcriptional regulation of anti-apoptotic proteins by miRNAs. This evidence concerns the gene BCL2 and Miyoshi myopathy.